Remdesivir Sharply Cuts COVID Hospitalization Risk, Gilead Says

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.

Remdesivir (Veklury, Gilead) was found to reduce some COVID-19 patients’ risk of hospitalization by 87% in a phase 3 trial, the drug’s manufacturer announced Wednesday in a press release.

The randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of a 3-day course of intravenous remdesivir in an analysis of 562 nonhospitalized patients at high risk for disease progression.

Remdesivir demonstrated a statistically significant 87% reduction in risk for COVID-19-related hospitalization or all-cause death by Day 28 (0.7% ) compared with placebo (5.3% [15/283]) P =.008. Participants were assigned 1:1 to remdesivir or the placebo group.

Researchers also found an 81% reduction in risk for the composite secondary endpoint — medical visits due to COVID-19 or all-cause death by Day 28. Only 1.6% had COVID-19 medical visits [4/246]) compared with those in the placebo group (8.3% [21/252]) P =.002. No deaths were observed in either arm by Day 28.

“These latest data show remdesivir’s potential to help high-risk patients recover before they get sicker and stay out of the hospital altogether,”  coauthor  Robert L. Gottlieb, MD, PhD, from Baylor University Medical Center in Houston, Texas, said in the press release.

Remdesivir is the only drug approved by the US Food and Drug Administration for hospitalized COVID-19 patients at least 12 years old. Its treatment of nonhospitalized patients with 3 days of dosing is investigational, and the safety and efficacy for this use and dosing duration have not been established or approved by any regulatory agency, the Gilead press release notes.

The patients in this study were considered high-risk for disease progression based on comorbidities — commonly obesity, hypertension, and diabetes — and age, but had not recently been hospitalized due to COVID-19.

A third of the participants were at least 60 years old. Participants in the study must have received a positive diagnosis within 4 days of starting treatment and experienced symptoms for 7 days or less.

Use of Remdesivir Controversial

Results from the Adaptive COVID-19 Treatment Trial (ACTT-1) showed remdesivir was superior to placebo in shortening time to recovery in adults hospitalized with COVID-19 with evidence of lower respiratory tract infection.

However, a large trial of more than 11,000 people in 30 countries, sponsored by the World Health Organization (WHO), did not show any benefit for the drug in reducing COVID deaths.

The WHO has conditionally recommended against using remdesivir in hospitalized patients, regardless of disease severity, “as there is currently no evidence that remdesivir improves survival and other outcomes in these patients.”

The drug also is given intravenously and this study tested three infusions over 3 days, a difficult treatment for nonhospitalized patients.

The study results were released ahead of IDWeek, where the late-breaking abstract will be presented at the virtual conference in full at the end of next week.

Marcia Frellick is a freelance journalist based in Chicago. She has previously written for the Chicago Tribune, Science News, and, and was an editor at the Chicago Sun-Times, the Cincinnati Enquirer, and the St. Cloud (Minnesota) Times. Follow her on Twitter at @mfrellick.

For more news, follow Medscape on Facebook, Twitter, Instagram, YouTube, and LinkedIn.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Even in the operating room, team chemistry matters, study finds thumbnail

Even in the operating room, team chemistry matters, study finds

Credit: CC0 Public Domain From flying a plane to swinging on a trapeze, there are plenty of high performance jobs where people must work closely together without making mistakes. Research into psychology and organizations has mostly concluded that the presence of positive emotions among team members generally improves performance across a range of occupations. But…
Read More
Bionic eye offers hope of restoring vision thumbnail

Bionic eye offers hope of restoring vision

Allen Zderad: I want to walk through the center of the door without any assistance. Dennis Douda: The next step Allen Zderad takes will be one of the greatest strides forward in his life. Allen Zderad: Right there. Dennis Douda: One that allows him to see his future in an entirely new way. Allen Zderad:
Read More
Top 7 cars in India with best safety rating thumbnail

Top 7 cars in India with best safety rating

The Safari has got a 5-star safety rating under the new testing protocol at Global NCAP.Tata SafariThe Harrier has also garnered a 5-star safety rating.Tata HarrierThe Taigun has high safety standards with a 5-star score at Global NCAP.Volkswagen TaigunLike the Taigun, the Virtus has also garnered a 5-star safety rating.Volkswagen VirtusSafety is the prime concern
Read More
Guess who's back:Rapper Eminem eröffnet ein Spaghetti-Restaurant in Detroit thumbnail

Guess who’s back:Rapper Eminem eröffnet ein Spaghetti-Restaurant in Detroit

Spaghetti allen Variationen: Eminem geht unter die Restaurantbetreiber. Imago Stock&people / Der US-Rapper Eminem (48) eröffnet in den USA ein Pasta-Restaurant. «Mom's Spaghetti» sollte am Mittwoch in der Metropole Detroit im US-Bundesstaat Michigan seine Türen öffnen, teilte der Musiker per Kurznachrichtendienst Twitter mit. Eminem veröffentlichte auch einen ersten Einblick in die Speisekarte, demzufolge es hauptsächlich Spaghetti…
Read More
Index Of News